Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Harris County Psychiatric Center (HCPC)
Houston, Texas, United States
Change in Suicidal Ideation and Behavior as assessed by an abbreviated version of the Columbia-Suicide Severity Rating Scale (CSSRS)
For the abbreviated, six-question version of the CSSRS, total scores range from 0 to 6 with a higher score indicating greater suicidal ideation and behavior.
Time frame: baseline, day 3
Change in Depression as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a ten item instrument, with each of the ten items rated on a scale of 0 to 6, giving a total score range of 0 to 60. A higher score indicates greater depression.
Time frame: baseline, day 3
Change in Suicidal Ideation as assessed by the Scale for Suicide Ideation (SSI)
The SSI is a nineteen item measure of current suicidal ideation and intention, with each item rated on a scale of 0 to 2, giving a total score range of 0 to 38. A higher score indicates greater suicidal ideation and intention.
Time frame: baseline, day 3
Change in Anxiety as assessed by the General Anxiety Disorder-7 (GAD-7)
The GAD-7 is a seven item instrument, with each of the 7 items is scored from 0 to 3, giving a total score range of 0 to 21. A higher score indicates greater anxiety.
Time frame: baseline, day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.